Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening

Tomohisa Tanaka \(^a\), Akatsuki Saito \(^b,c\), Tatsuya Suzuki \(^d\), Yoichi Miyamoto \(^e\), Kazuo Takayama \(^f\), Toru Okamoto \(^g\), Kohji Moriishi \(^a,g,h,\text*}\)

\(^a\) Department of Microbiology, Faculty of Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Yamanashi, 409-3898, Japan
\(^b\) Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, 889-2192, Japan
\(^c\) Center for Animal Disease Control, University of Miyazaki, Miyazaki, 889-2192, Japan
\(^d\) Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan
\(^e\) Laboratory of Nuclear Transport Dynamics, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan
\(^f\) Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, 606-8507, Japan
\(^g\) Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan
\(^h\) Division of Hepatitis Virology, Institute for Genetic Medicine, Hokkaido University, Hokkaido, 060-0808, Japan

**ARTICLE INFO**

**Keywords:**
- Antiviral
- SARS-CoV-2
- Replicon
- Stable cell line

**ABSTRACT**

Experiments with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are limited by the need for biosafety level 3 (BSL3) conditions. A SARS-CoV-2 replicon system rather than an in vitro infection system is suitable for antiviral screening since it can be handled under BSL2 conditions and does not produce infectious particles. However, the reported replicon systems are cumbersome because of the need for transient transfection in each assay. In this study, we constructed a bacterial artificial chromosome vector (the replicon-BAC vector) including the SARS-CoV-2 replicon and a fusion gene encoding Renilla luciferase and neomycin phosphotransferase II, examined the antiviral effects of several known compounds, and then established a cell line stably harboring the replicon-BAC vector. Several cell lines transiently transfected with the replicon-BAC vector produced subgenomic replicon RNAs (sgRNAs) and viral proteins, and exhibited luciferase activity. In the transient replicon system, treatment with remdesivir or interferon-β but not with camostat or favipiravir suppressed the production of viral agents and luciferase, indicating that luciferase activity corresponds to viral replication. VeroE6/Rep3, a stable replicon cell line based on VeroE6 cells, was successfully established and continuously produced viral proteins, sgRNAs and luciferase, and their production was suppressed by treatment with remdesivir or interferon-β. Molnupiravir, a novel coronavirus RdRp inhibitor, inhibited viral replication more potently in VeroE6/Rep3 cells than in VeroE6-based transient replicon cells. In summary, our stable replicon system will be a powerful tool for the identification of SARS-CoV-2 antivirals through high-throughput screening.

**1. Introduction**

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a global threat to public health. Up to 80% of people infected with SARS-CoV-2 exhibit asymptomatic cases or mild-to-moderate respiratory illness, while some patients progress to severe pneumonia, acute respiratory distress, septic shock and multiple organ failure (Cao, 2020; Huang et al., 2020). As of November 2021, more than 200 million people have been affected by COVID-19, and approximately 5 million deaths have

**Abbreviations:** COVID-19, Coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RdRp, RNA polymerase; N, Nucleocapsid; BSL, biosafety level; sgRNA, subgenomic RNA; BAC, bacterial artificial chromosome; The replicon-BAC vector, aBAC vector encoding SARS-CoV-2 reporter replicon RNA with a fusion gene encodingRenilla luciferase and neomycin phosphotransferase II; IFN, interferon; DAPI, diamidino-2-phenylindole; CMV, cytomegalovirus; CMVp, cytomegalovirus promoter; CPER, circular polymerase extension reaction; UTR, untranslated region; TRS, transcription-regulating sequence; nsp, nonstructural protein; DMSO, dimethyl sulfoxide; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.

* Corresponding author. Department of Microbiology, Faculty of Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, 1110 Shimo-makoto, Chuo-shi, Yamanashi, 409-3898, Japan.

**E-mail address:** kmoriishi@yamanashi.ac.jp (K. Moriishi).

https://doi.org/10.1016/j.antiviral.2022.105268

Received 13 January 2022; Received in revised form 16 February 2022; Accepted 22 February 2022

Available online 7 March 2022

0166-3542/© 2022 Elsevier B.V. All rights reserved.
been reported worldwide (Yang and Rao, 2021). Some of the current vaccines against the SARS-CoV-2 spike protein are highly effective, while several amino acid residues in the viral spike protein have been reported to be mutated, leading to impairment of vaccine efficacy (Collier et al., 2021; Harvey et al., 2021). Neutralizing antibody cocktails targeting the spike protein and small chemicals such as remdesivir, molnupiravir and some protease inhibitors have been developed for the treatment of COVID-19 (Bakowski et al., 2021; Choy et al., 2020; Group, 2020; Sheahan et al., 2020). However, more effective antivirals and vaccines are still needed.

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Betacoronavirus, subgenus Sarbecovirus. Two viral polyproteins (pp1a and 1ab) are cleaved into 16 nonstructural proteins, which constitute the replication and transcription complex to initiate viral RNA replication and transcription (Snijder et al., 2016; Yang and Rao, 2021). Nsp12 possesses RNA polymerase activity and forms a tripartite complex with nsp7 and nsp8 to produce the RNA-dependent RNA polymerase (RdRp) complex (Snijder et al., 2016). Nucleocapsid (N) protein binds to viral genomic RNA to form the ribonucleocapsid and helps regulate discontinuous transcription of subgenomic RNAs (sgRNAs) through RNA chaperone activity (Grossoehme et al., 2009; McBride et al., 2014; Sunjiga et al., 2010).

Since experimental infection with SARS-CoV-2 must be restricted under the condition of biosafety level 3 (BSL3), BSL2-compatible SARS-CoV-2 replicon systems have been developed instead of in vitro infection models for basic research and antiviral screening (He et al., 2021; Kotaki et al., 2021; Nguyen et al., 2021; Zhang et al., 2021). Nguyen et al. prepared a bacterial artificial chromosome (BAC) vector encoding SARS-CoV-2 replicon RNA under the control of the CMV promoter (Nguyen et al., 2021), while others have made transient replicon systems using in vitro transcribed SARS-CoV-2 replicon RNA (He et al., 2021; Kotaki et al., 2021; Zhang et al., 2021). In each replicon system, the expression of luciferase or a fluorescent reporter gene of replicon RNA is induced in a replication-dependent manner. These replicon systems could be applicable to screening for antiviral compounds targeting SARS-CoV-2 replication, although transient transfection with these vectors or RNAs is still needed for each replicon assay, leading to cumbersome application for studies such as high-throughput screening. Thus, establishment of a cell line harboring stable replication of the SARS-CoV-2 replicon is required for drug screening.

In this study, we prepared a BAC vector encoding SARS-CoV-2 reporter replicon RNA with a fusion gene encoding Renilla luciferase and neomycin phosphotransferase II (the replicon-BAC vector), examined the antiviral effects of remdesivir, molnupiravir, type I interferon (IFN), camostat and favipiravir on viral replication in the transient system using the replicon-BAC vector, and established a cell line that stably supports the replication of the replicon. Furthermore, we examined the production of viral factors and the antiviral effect of the reported compounds in the stable replicon cell line. Our stable replicon system for SARS-CoV-2 will be a powerful tool for high-throughput screening for clinically available antivirals.

2. Materials and methods

2.1. Reagents and cells

We purchased favipiravir, camostat mesylate and remdesivir from Cayman Chemicals (Ann Arbor, MI), EIDD-2801 (molnupiravir) from MedChemExpress (Monmouth Junction, NJ), recombinant human IFN-β from PeproTech (rocky Hill, NJ), and diamidino-2-phenyindole (DAPI) from Dojin Chemical (Kumamoto, Japan). The following antibodies were used in this study: mouse anti-SARS-CoV-2 nucleocapsid (N) monoclonal antibody (3A9; Cell Engineering Co. Osaka, Japan), mouse anti-SARS-CoV-2 nsp8 antibody (5A10; GeneTex, Irvine, CA), mouse anti-β-actin antibody (AC-74; Sigma–Aldrich), HRP-conjugated rabbit anti-mouse IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and Alexa 488-conjugated goat anti-mouse IgG antibody (Thermo Fisher Scientific, Waltham, MA). The human embryonic kidney 293T, human hepatoma HuH7 and African green monkey kidney VeroE6 cell lines were cultured in DMEM (Sigma–Aldrich, St. Louis, MO) supplemented with 10% FBS (Gibco, Cambrex, MD) and 1% sodium pyruvate (Sigma–Aldrich), 1% nonessential amino acid (Sigma–Aldrich) and 1% penicillin–streptomycin solutions (Nacalai Tesque, Kyoto, Japan). HuH7, 293T and VeroE6 cell lines were kindly provided by Prof. Y. Matsuura (Osaka University, Osaka, Japan). G418 (Nacalai Tesque) was further added to the culture medium at a final concentration of 1 mg/ml for the establishment and maintenance of the VeroE6/Rep cell line. All cell lines were cultured at 37 °C in a 5% CO2 humidified atmosphere. SARS-CoV-2 strain Hu/DP/Kng/19-020 (GenBank accession no. LC528232.2) was kindly provided by Dr Jun-ichi Sakuragi at the Kanagawa Prefectural Institute of Public Health.

2.2. Cloning, preparation and transfection of the BAC vector

Overviews of the design and construction of the replicon-BAC vector (pBAC-S-CoV2-Rep-Reo) are shown in Fig. 1. The region including the viral replicase complex was amplified from the cells infected with SARS-CoV-2/Hu/DP/Kng/19-020 (GenBank accession no. LC528232.2). CPER enables direct synthesis of infectious cDNA of flaviviruses and SARS-CoV-2 from DNA fragments without in vitro ligation (Edmonds et al., 2013; Kotaki et al., 2021; Quan and Tian, 2009; Torii et al., 2021). First, we generated a pBAC cassette vector that encodes the cytomegalovirus (CMV) immediate-early promoter (CMVP) immediately upstream of the 5’ UTR of SARS-CoV-2 and the N gene followed by the 3’ UTR, synthetic 25-nt polyA, the hepatitis delta virus ribozyme and BHG polyadenylation sequences, as the PCR template for fragment F10 (Fig. 1A), according to the method of Edmonds et al. (2013). Eight fragments covering the replicase complex-encoding region were subcloned into pCR-blunt (Invitrogen) as templates for fragments F1 to F8 (Fig. 1A). Fragment F9, which is composed of, in order, a spacer (AscI site), the 3’-end portion of ORF8, TRS-B, the Reo gene, a spacer (BamHI site), the 3’-end portion of ORF8, and TRS-B, was subcloned into pCR-blunt (Fig. 1A). Eight fragments covering the region encoding the replicase complex (F1 to F8 in Fig. 1A) were amplified by PCR using the primers listed in Table 1 and then cloned into pCR-Blunt (Invitrogen). To construct the pBAC cassette, the CMVP and the 5’-terminal region of SARS-CoV-2 (nt 1–683) were amplified by PCR from pcDNA3.1 and viral cDNA, respectively, combined by overlap PCR, and then cloned into pSMART-BAC v2.0 (Lucigen Corp., Middletown, WI). Subsequently, the 3’-terminal region of SARS-CoV-2 (nt 28,134–29,902) and polyadenylation sequence were amplified by PCR from the viral cDNA and pcDNA3.1, respectively, connected across the synthesized sequence consisting of 25-nt polyA and the hepatitis delta virus ribozyme (Almazan et al., 2006) by overlap PCR, and cloned into the BAC described above. The resulting pBAC cassette was used as the template for F10 production (Fig. 1A). Finally, the ten PCR fragments (F1 to F10) were mixed at an equal amount (0.05 pmol each) in 50 μl of the reaction buffer for PrimerSTAR GXL DNA polymerase (Takara Bio, Shiga, Japan) and assembled in vitro by CPER (Edmonds et al., 2013; Torii et al., 2021). The CPER was carried out as follows: one cycle of 98 °C for 2 min; 20 cycles of 98 °C for 10 s, 55 °C for 15 s and 68 °C for 30 min; and one cycle of 68 °C for 30 min following by holding at 4 °C. The resulting solution was extracted with phenol–chloroform–isoamyl alcohol, recovered by ethanol precipitation, dissolved in TE buffer, and introduced into BAC-Optimized Replicator v2.0 electrocompetent cells (Lucigen Corp.) according to the manufacturer’s protocol. The resulting vector was designated pBAC-S-CoV2-Rep-Reo. DNA preparation was carried out using NucleoSpin (Takara Bio) and NucleoBond Xtra BAC Kits (Takara Bio) for small-scale and large-scale replicon-BAC vector preparation, respectively. Transfection of the replicon-BAC vector was performed using TransIT-LT1 reagent (Mirus, Madison, WI).
Fig. 1. Construction of the BAC vector encoding the SARS-CoV-2 reporter replicon and structure of the transcribed genes encoded on the vector. (A) A schematic diagram of the strategy for cloning the BAC vector encoding the SARS-CoV-2 reporter replicon. PCR fragments F1 to F10 were amplified from subcloning or cassette vectors by PCR using the primers listed in Table 1 as described in Materials and Methods and then subjected to CPER. The resulting vector was designated pBAC-SCoV2-Rep-Reo. The numbers inside the parentheses represent the nucleotide positions in the SARS-CoV-2/Hu/DP/Kng/19–020 genome. TRSs in the leader sequence of the 5′ UTR (TRS-L) and in the genome body (TRS-B) are indicated as a white arrowhead and a black arrowhead, respectively. The blue line indicates the pSMART-BAC v2.0 vector sequence. Reo, a fusion gene consisting of Renilla luciferase and neomycin phosphotransferase; CMVp, cytomegalovirus promoter; 5′, 5′ UTR; 3′, 3′ UTR; pA, synthetic 25-poly(A); Rz, hepatitis delta virus ribozyme; BGH, bovine growth hormone termination and polyadenylation sequence. Refer to Fig. 1B for detailed information on fragment F9 and the intermediate sequence between the ORF1ab and N genes in pBAC-SCoV2-Rep-Reo. (B) Structure of the replicon-BAC vector. The region between the ORF1b and N genes in pBAC-SCoV2-Rep-Reo (the lower diagram) is magnified and shown in the upper diagram, corresponding to PCR fragment F9 (Fig. 1A). The numbers inside the parentheses represent the nucleotide positions in the SARS-CoV-2/Hu/DP/Kng/19-020 genome. (C) A schematic diagram of the production of sgRNAs. The upper diagram indicates full replicon RNA. The RNA transcribed under the control of the CMV promoter is processed by the ribozyme into full replicon RNA (sgRNA1). White and black arrowheads indicate the positions of TRS-L and TRS-B, respectively. sgRNA1 corresponding to full-length RNA and two sgRNAs (sgRNA2 and 3) are generated by discontinuous transcription mediated by the RNA-RNA interaction between TRS-L and TRS-B. sgRNA1, 2 or 3 serves as the translation template for polyprotein, Reo or N protein, respectively. Arrows indicate the location and orientation of the primers used for the detection and quantification of sgRNA3 (Table 1).
2.3RT–PCR and quantitative RT–PCR (qRT–PCR)

Total RNA was extracted from cells using an RNeasy Mini Kit (Qia-gen, Valencia, CA) and reverse transcribed using ReverTra Ace qPCR RT Master Mix (Toyobo, Tokyo, Japan). RT–PCR was performed to detect sgRNA3 and GAPDH mRNA by using Quick Taq HS Dye Mix (Toyobo). The expression level of sgRNA3 was calculated by the relative threshold cycle (ΔΔCt) method using GAPDH mRNA as an internal control.

The primers for RT–PCR and qRT–PCR are listed in Table 1.

2.4Northern blotting

Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA), precipitated, dissolved in RNase-free water and treated with a TURBO DNA-Free Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. The resulting preparations were then mixed with a formaldehyde loading dye (Ambion). The samples were denatured at 65 °C for 15 min, chilled on ice, and electrophoresed through a 1% agarose gel containing formaldehyde. A DIG-labeled Molecular Weight Marker I (Roche, Mannheim, Germany) was employed as RNA size marker. The separated RNA in the gel was stained with ethidium bromide (EtBr). After capillary transfer onto a positively charged nylon membrane (Roche), the membrane was subjected to UV fixation and then Northern blotting as reported previously (Otoguro et al., 2021). The signals were visualized with CDP-star (Roche) and LAS-4000 Mini (Fuji Film). The expression level of sgRNA3 was calculated by the relative threshold cycle (ΔΔCt) method using GAPDH mRNA as an internal control.

The primers for RT–PCR and qRT–PCR are listed in Table 1.
3. Results

3.1. Development of the BAC vector encoding the SARS-CoV-2 reporter replicon

Several groups have reported the development of SARS-CoV-2 replicon systems (Kotaki et al., 2021), while the development of a cell clone stably replicating the replicon has not yet been reported. In this study, we constructed a SARS-CoV-2-based selectable reporter replicon encoding a fusion gene encoding Renilla luciferase and neomycin phosphotransferase (Reo) to establish a stable SARS-CoV-2 replicon cell line. The reporter replicon cDNA was engineered with a BAC due to the large size and to achieve stability of the coronavirus replicase gene (Kotaki et al., 2021). We employed the circular polymerase extension reaction (CPER) method to assemble the BAC vector containing SARS-CoV-2 replicon cDNA (Edmonds et al., 2013; Torii et al., 2021). Eight fragments covering the region encoding nonstructural polyproteins were subcloned into pCR-blunt (Invitrogen) as templates for fragments F1 to F8 (Fig. 1A). Fragment F9, which is composed of, in order, a spacer (AscI site), the 3′-end portion of ORF8, transcription-regulating sequence (TRS)-body (TRS-B), the Reo gene, a spacer (BamHI site), the 3′-end portion of ORF8, andTRS-B, was subcloned into pCR-blunt (Fig. 1A and B). The expression mechanism of the reporter replicon post-vector delivery is illustrated in Fig. 1C. The BAC vector-encoded replicon cDNA is transcribed from the CMVp by the host RNA polymerase complex into the replicon mRNA, which is processed by ribozyme-mediated self-cleavage to generate full-length replicon RNA (Fig. 1C). The full replicon RNA contains three TRSs: one TRS in the leader sequence of the 5′ untranslated region (UTR) (TRS-L) and two TRSs upstream of the Reo and N genes (TRS-B). TRSs allow recombination between TRS-L and TRS-B to produce sgRNAs in a replication-dependent manner (Fig. 1C).

3.2. Selection of the replication-competent pBAC-SCoV2-Rep-Reo

To assemble the BAC vector pBAC-SCoV2-Rep-Reo, fragments F1 to F10, each of which possesses approximately 30-nt overlapping ends for two neighboring fragments, were amplified by PCR using individual primers (Table 1) and subjected to CPER. For the selection of transformant colonies carrying the CPER product (Fig. 2A), each DNA preparation extracted from 20 colonies was introduced into 293T cells by lipofection. Following transfection, RT–PCR specific for sgRNA3 using primers 1 and 2 (Fig. 1C, Table 1) and luciferase assays were carried out to find replication-competent BAC clones. Ten clones were positive for fragments F1 to F8 (Fig. 1A). Fragment F9, which is composed of, in order, a spacer (AscI site), the 3′-end portion of ORF8, transcription-regulating sequence (TRS)-body (TRS-B), the Reo gene, a spacer (BamHI site), the 3′-end portion of ORF8, andTRS-B, was subcloned into pCR-blunt (Fig. 1A and B). The expression mechanism of the reporter replicon post-vector delivery is illustrated in Fig. 1C. The BAC vector-encoded replicon cDNA is transcribed from the CMVp by the host RNA polymerase complex into the replicon mRNA, which is processed by ribozyme-mediated self-cleavage to generate full-length replicon RNA (Fig. 1C). The full replicon RNA contains three TRSs: one TRS in the leader sequence of the 5′ untranslated region (UTR) (TRS-L) and two TRSs upstream of the Reo and N genes (TRS-B). TRSs allow recombination between TRS-L and TRS-B to produce sgRNAs in a replication-dependent manner (Fig. 1C).

3.3. Transient expression of the SARS-CoV-2 reporter replicon in cell culture

We examined whether pBAC-SCoV2-Rep-Reo was active in a transient replicon assay. N protein was detected in VeroE6 cells transfected with the replicon-BAC vector (Fig. 3A). We transiently transfected the replicon-BAC vector into 293T, Huh7 and VeroE6 cells and then cultured the resulting cells in the presence of IFN-β or remdesivir (Let et al., 2020; Zhao et al., 2021a). N protein was expressed in the cell lines transfected with the replicon-BAC vector (Fig. 3B), and its expression level was reduced by treatment with IFN-β or remdesivir, depending on the cell line (Fig. 3B), suggesting replication-dependent expression of the N protein. Treatment with IFN-β reduced N protein expression in Huh7 and VeroE6 cells but not 293T cells. In contrast, treatment with remdesivir reduced N protein expression in 293T and Huh7 cells but weakly in VeroE6 cells (Fig. 3B). Additionally, nsp8, a component of the viral replicase complex, was detected in the transfected 293T cells, and its expression was reduced by remdesivir, suggesting that polyproteins 1a and 1 ab were expressed and processed into mature nonstructural proteins (Fig. 3B). Nsp8 was undetectable in Huh7 and VeroE6 cells by Western blotting, probably due to limited transfection efficiency in these cell lines (Fig. 3B). Additionally, we analyzed the replicon RNA extracted from the transfected 293T cells by Northern blotting using a probe specific for the N gene. Three sgRNAs (sgRNA1, 2 and 3, Fig. 1C) with distinct predicted sizes were detected by Northern blotting (Fig. 3C). Interestingly, the sgRNA3 level was clearly decreased by treatment with remdesivir but not by treatment with IFN-β in 293T cells (Fig. 3C). The reduction in the sgRNA3 level by remdesivir treatment was confirmed quantitatively by qRT–PCR (Fig. 3D). The effects of IFN-β and remdesivir on the level of sgRNA3 were well correlated with their effects on the level of N protein in 293T, Huh7 and VeroE6 cells (Fig. 3B, D). Luciferase activities in 293T, Huh7 and VeroE6 cells transfected with the replicon-BAC vector were significantly reduced by treatment with IFN-β and/or remdesivir (Fig. 3E). Consistent with the Western blotting and qRT–PCR data (Fig. 3B, D), IFN-β and remdesivir significantly impaired luciferase expression in the Huh7 and VeroE6 cell lines transfected with the replicon-BAC vector, while viral replication in 293T cells was resistant to IFN-β (Fig. 3E). These data suggest that SARS-CoV-2 replication can be monitored by the reporter assay.

Recently, camostat mesylate, an inhibitor of TMPRSS2, was shown to inhibit SARS-CoV-2 entry (Cheng et al., 2020; Hoffmann et al., 2020, 2021). Favipiravir (Avigan), a nucleoside analog, has been shown to have antiviral activity in vivo assays and clinical studies (Kaptein et al., 2020; Martinez, 2020) and to suppress viral replication via inhibition of viral RdRp at a high dose up to 100 μM (Shannon et al., 2020;
Zhao et al., 2021a), whereas some reports show no obvious inhibition of virus proliferation upon treatment with favipiravir (Choy et al., 2020; Pizzorno et al., 2020). Luciferase activity was not reduced by treatment with 10 μM favipiravir in 293T cells transfected with the replicon-BAC vector (Fig. 3F), suggesting that the transient replicon system is applicable to the assessment of antiviral effects on specifically SARS-CoV-2 replication.

3.4. Establishment of a VeroE6-based cell line harboring a functional SARS-CoV-2 replicon with luciferase expression

We attempted to establish a stable replicon cell line using pBAC-SCoV2-Rep-Reo. Because the replicon-BAC vector was designed to confer neomycin resistance to cells, we cultured Huh7 and VeroE6 cells transfected with the replicon vector in medium containing G418. A number of colonies were generated by the transfection of VeroE6 cells with the replicon-BAC vector (Fig. 4A) but not by transfection of Huh7 cells with the vector (data not shown). We established 14 cell clones from these colonies. Since the expression of the reporter and sgRNAs requires TRS-mediated discontinuous transcription, we evaluated cellular luciferase activity in each clone. A higher level of luciferase activity was observed in clone nos. 1, 3, 4, 6 and 13 than in the other clones (Fig. 4B; nos. 1, 3, 4, 6 and 13). However, sgRNA3 was detected in clone no. 3 but not in the other clones (Fig. 4C). Therefore, clone no. 3 was analyzed further as a stable replicon cell line, designated VeroE6/Rep3. To assess the sustainability of persistent reporter expression in
VeroE6/Rep3 cells, we serially passaged the cells in the presence or absence of G418. The luciferase activity in VeroE6/Rep3 cells was maintained for at least 4 weeks in the presence of G418 (Fig. 4D). The luciferase activity was also maintained but decayed when the cells were cultured for 2 weeks in the absence of G418 (Fig. 4D). Therefore, it is better to maintain VeroE6/Rep3 cells in the presence of G418, while the medium can also be replaced with G418-free medium during short-term assays.

To determine whether the replicon was actively replicated in the VeroE6/Rep3 cell line, we evaluated the intracellular levels of N protein and sgRNAs in the presence or absence of IFN-β or remdesivir. The amount of N protein in the lysate prepared from VeroE6/Rep3 cells was similar to the amount in the lysate from VeroE6 cells transiently transfected with the vector (Fig. 5A) and was reduced by treatment with IFN-β or remdesivir (Fig. 5A), suggesting that VeroE6/Rep3 cells express N protein in a replication-dependent manner. Northern blotting data indicated that sgRNAs 1, 2 and 3 were expressed in the VeroE6/Rep3 cell line but not in the parent VeroE6 cell line (Fig. 5B). N protein was expressed in VerpE6/Rep3 cells, but not in VeroE6 cells (Fig. 5C). Treatment with IFN-β decreased the levels of all sgRNAs, while treatment with remdesivir decreased the amount of sgRNA3 more potently than those of sgRNAs 1 and 2 (Fig. 5D). Furthermore, treatment with IFN-β or remdesivir reduced luciferase expression in VeroE6/Rep3 cells, although the inhibitory effect of remdesivir was lower than that of IFN-β (Fig. 5E), which is consistent with their effects on the level of N protein (Fig. 5A). These data suggest that luciferase activity is correlated with the replication level in VeroE6/Rep3 cells.

3.5. Effect of EIDD-2801 on SARS-CoV-2 replication

EIDD-2801 (molnupiravir), a prodrug of the ribonucleoside analog β-D-N4-hydroxycytidine (NHC), was recently reported to exhibit potent antiviral activity against SARS-CoV-2 in vivo and in vitro (Bakowski et al., 2021; Painter et al., 2021; Sheahan et al., 2020; Wahl et al., 2021). The in vitro reporter system for the analysis of SARS-CoV-2 RdRp activity showed that EIDD-2801 effectively inhibited RdRp activity with an IC_{50} value of 0.22 μM (Zhao et al., 2021a). We examined the effect of EIDD-2801 on viral replication using our transient and stable replicon systems. The luciferase activity was dose-dependently reduced by treatment with EIDD-2801 in Huh7 cells but not 293T cells transiently transfected with the BAC vector (Fig. 6A). EIDD-2801 effectively inhibited replication in Huh7 cells but not remarkably in VeroE6 cells (Fig. 6A). The IC_{50} value of EIDD-2801 in transfected Huh7 cells was calculated to be approximately 2.2 μM. On the other hand, the luciferase activity was also reduced by EIDD-2801 treatment in a dose-dependent manner in VeroE6/Rep3 cells (Fig. 6A and B), and the drug effect appeared more remarkable in VeroE6/Rep3 cells than in VeroE6 cells transfected with the replicon-BAC vector (Fig. 6A and B). The IC_{50} value of EIDD-2801 in transfected Huh7 cells was calculated to be approximately 4.3 μM. These data suggest that our transient and stable replicon systems provide insight into the replication mechanisms of SARS-CoV-2 and contribute to the development of antiviral agents against SARS-CoV-2 under BSL-2 conditions.

4. Discussion

One of the advantages of the CPER method is the ease of
modification; site-directed mutation in infectious or replicon cDNA of SARS-CoV-2 can be achieved through the modification of individual subcloning vectors. Several therapeutic agents for SARS-CoV-2 are eagerly anticipated and will be put into practical use, while antiviral administration potentially involves the risk of the development of drug-resistant variants. The construction of replicon vectors by the CPER method provides an immediate response to the investigation of drug resistance and other novel mutants. We showed that the inhibitory effects of remdesivir, IFN-β and EIDD-2801 on replication varied among 293T, Huh7 and VeroE6 cells (Fig. 3B–E, Fig. 6). The differences in drug efficacy may be attributed to the cell-type characteristics of membrane permeability, efflux, metabolic pathway activation and IFN-β response. Thus, the option of cell types will be advantageous for the exploration of viral replication and drugs. It would be burdensome to conduct a DNA transfection step for the transient replicon system and to prepare a sufficient amount of high-grade BAC vector because a BAC vector with a large molecular size is expected to be prepared at a low yield. On the other hand, stable replicon systems, such as the VeroE6/Rep3 cell line, do not require transfection for each assay or vector preparation. Thus, the stable replicon system seems to be appropriate for high-throughput screening rather than the transient replicon system. The dose dependency of the reduction in the replicon replication level by treatment with EIDD-2801 was clearer in VeroE6/Rep3 cells than in VeroE6 cells harboring the transient replicon (Fig. 6). In the transient replicon system, heterogeneity in transfection efficiency and cytotoxicity of transfection may lead to variability in the data. In contrast, the effect of IFN-β and remdesivir on the replication of replicon in VeroE6/Rep3 cells is similar to that in the transient replicon system using transient replicon system (Figs. 3E and 5E), suggesting that both indicate antiviral effects on the replication regardless of the side effects related with transient
ns, no significance). There was no significant difference in cell viability between the two models. Significance was calculated compared to the mock group (*, p < 0.05; **, p < 0.01; ns, no significance). There was no significant difference in cell viability (not shown).

DNA transfection. It will be important to choose between the two models depending on the purpose of the experiment.

Unfortunately, we could not establish another cell line persistently expressing the replicon in this study. The replicon vector was unstable in the Huh7 cell line and eradicated during a cloning step. Furthermore, a recent report suggested that the establishment of stable replicon cells is unsuccessful due to the toxicity derived from a viral protein or a replication step (He et al., 2021). Among the viral proteins translated from replicon sgRNAs, nonstructural protein 1 (nsp1) has been shown to be a viral cytotoxic factor (Yuan et al., 2020). Nsp1 plays an important role in the shut-off of host protein synthesis during SARS-CoV-2 replication (Thoms et al., 2020). Additionally, its expression has been shown to trigger cell cycle arrest and cell death (Shen et al., 2021; Thoms et al., 2020). Thus, nsp1-induced cytotoxicity in replicon-expressing cells is thought to interfere with the establishment of stable replicon cells. On the other hand, VeroE6 cells are known to lack type I IFN production and the expression of key factors in cell cycle regulation, including cyclin-dependent kinase inhibitors 2A and 2B (Osada et al., 2014). The characteristics of VeroE6 cells may contribute to the establishment of a stable cell line harboring the SARS-CoV-2 replicon.

The data in Figs. 3C and 5D indicated that treatment with remdesivir potently reduced the synthesis of sgRNA3 more than that of other sgRNAs in the transient and stable replicon models. Remdesivir is a nucleoside analog prodrug that is converted into the active triphosphate form (Siegel et al., 2017). The triphosphate form is used by viral RdRp instead of nucleoside triphosphates, resulting in subsequent RdRp stalling (Gordon et al., 2020; Kokie et al., 2021). Furthermore, remdesivir has been shown to inhibit the synthesis of negative-strand RNA more potently than that of positive-strand RNA and to change the component ratios of sgRNAs generated by both canonical and noncanonical template-switching events (Zhao et al., 2021b). The dominant effect of remdesivir on the synthesis of sgRNA3 may be derived from dysregulation in both canonical and noncanonical template-switching events in the replicon cells.

EIDD-2801, a prodrug of β-DN 4-hydroxycytidine (NHC), effectively suppressed viral replication in the transient and stable replicon assays (Fig. 6) and has been shown to potently inhibit SARS-CoV-2 replication in vivo and in vitro (Sheahan et al., 2020). The prodrug is intracellularly converted to the triphosphate form, which is a competitive substrate for CTP or UTP during the RdRp reaction. Thus, the metabolic pathway may be defective in 293T cells (Fig. 6A). On the other hand, EIDD-2801 dose-dependently inhibited SARS-CoV-2 particle production in VeroE6 cells expressing TMPRSS2 (Szemiel et al., 2021), suggesting that the VeroE6/Rep cell line is capable of supporting the metabolic activation of EIDD-2801. The IC50 value of EIDD-2801 on SARS-CoV2 infection of TMPRSS2-expressing VeroE6 cell line was reported to be approximately 9 μM (Szemiel et al., 2021), which is similar to the value obtained using our system (4.3 μM).

In this study, we established transient and stable replicon systems of SARS-CoV-2. The transient replicon system will be available for the comparison of drug efficiency or replication activity among various cell types, while the stable replicon system using VeroE6/Rep3 cells is suggested to be suitable for applications with high-throughput screening. Our replicon systems will be helpful to advance knowledge in the field of research on the mechanism of SARS-CoV-2 replication and the development of effective antiviral agents or vaccines for clinical use.

Funding

This work was supported by the Japan Agency for Medical Research and Development (AMED, Japan; Grant numbers, 20fk0108263, 20fk0108518, 20fk0108471) and Japan Science and Technology (JST, Japan; Grant number Moonshot R&D JPMJMS2025).

Author contributions

T.T., A.S. and T.S. performed the cloning and construction of vectors; A.S., Y.M., T.S. and K.T. provided critical materials and scientific insights; T.T. performed experiments; T.T., T.O., K.T. and K.M. analyzed the data; and T.T., K.T. and K.M. wrote the manuscript.
Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank the M. Mori for their assistance. We are also grateful to Jun-ichi Sakuragi, Kanagawa Prefectural Institute of Public Health, for providing SARS-CoV-2 and to Yoshiharu Matsuura, Osaka University, for providing cell lines.

References

Almazan, F., Dediego, M.I., Galan, C., Escors, D., Alvarez, E., Ortego, J., Sola, I., Zuniga, S., Alonso, S., Moreno, J.I., et al., 2006. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J. Virol. 80, 19090–19096.

Bakowski, M.A., Beutler, N., Wolff, K.C., Kirkpatrick, M.G., Chen, E., Nguyen, T.H., Riva, L., Shabani, N., Parren, M., Ricketts, J., et al., 2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 12, 3309.

Cao, X. 2020. COVID-19: immunopathogenesis and its implications for therapy. Nat. Rev. Immunol. 20, 269–270.

Cheng, Y.W., Chao, T.J., Li, C.L., Chiu, M.F., Kao, H.C., Wang, S.H., Pang, Y.H., Lin, C.H., Tsay, Y.M., Lee, W.H., et al., 2020. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 33, 108254.

Choy, K.T., Meng, B., Collier, D.A., De Marco, A., Ferreira, I., Choy, K.T., Wong, A.Y., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K.P.Y., Chu, D.K.W., Tanaka et al., 2020. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 11, 4682.

Sharma, A., Sims, A.C., Zhou, S., Graham, R.L., Pujiasjes, A.J., Agostini, M.L., Leist, S.R., Schafer, A., Dinndorf, K.J., Stevens, L.J., et al., 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883.

Shen, Z., Zhang, Y., Yang, Y., Li, M., Yang, S., Feng, G., et al., 2021. Lysine 164 is critical for SARS-CoV-2 Nsp1 inhibition of host gene expression. J. Gen. Virol. 102, gjv001513.

Siegel, D., Hui, H.C., Doerffler, E., Clarke, M.O., Chun, K., Zhang, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al., 2017. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][1,2,4-triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J. Med. Chem. 60, 1648–1661.

Snijder, E.J., Decroly, E., Ziebuhr, J., 2016. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv. Virus Res. 96, 59–125.

Szmigielski, A.M., Merits, A., Orton, R.J., MacLean, O.A., Pinto, R.M., Wickenhagen, A., Lieber, G., Turnbull, M.M., Wang, S., Fumon, W., et al., 2021. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 17, e1009929.

Tanaka, T., Okuyama-Dobashi, K., Motohashi, R., Yokohe, T., Takahashi, K., Wiriyasermkul, P., Kashi, H., Yamashita, A., Maekawa, S., Enomoto, N., et al., 2021. Inhibitory effect of a novel thiazolidinedione derivative on hepatitis B virus entry, virus replication and release. J. Virol. 95, e00700–e00721.

Thoms, M., Buchrauer, S., Ametsmeier, M., Koepke, L., Denk, T., Hirschenberger, M., Schwaab, K., Balsamo, L., Enomoto, N., et al., 2021. CAMSTATmesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its impact on the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 11, 6342.

Torii, S., Ono, C., Suzuki, R., Morioka, Y., Azain, I., Fuzayry, Y., Maeda, Y., Kamitani, W., Fukuhara, T., Matsuura, Y., 2021. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 35, 109014.

Van, W., Gris, A., Slavik, B., Le, N.T., Huchting, J., Touret, F., Piorkowski, G., Attini, N., Perrin, F., Decroly, E., Meier, C., et al., 2020. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 11, 6342.

Wiemken, A., Padey, B., Dubois, J., Brun, P., Lina, B., Rosa-Calatrava, M., Terrier, O., 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antivir. Res. 181, 104978.

Kaptein, S.J.F., Jacobs, S., Langendries, L., Seldeslachts, L., Ter Horst, S., Lienenbeeks, L., Hens, B., Vergote, V., Heylen, E., Barthelemy, K., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Kaptein, S.J.F., Jacobs, S., Langendries, L., Seldeslachts, L., Ter Horst, S., Lienenbeeks, L., Hens, B., Vergote, V., Heylen, E., Barthelemy, K., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Kaptein, S.J.F., Jacobs, S., Langendries, L., Seldeslachts, L., Ter Horst, S., Lienenbeeks, L., Hens, B., Vergote, V., Heylen, E., Barthelemy, K., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.